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Abstract
Background: The GIHU004 study was designed to evaluate the safety and immunogenicity of three doses of DermaVir
immunization in HIV-infected subjects on fully suppressive combination antiretroviral therapy (cART).
Methodology/Principal Findings: This first-in-human dose escalation study was conducted with three topical DermaVir
doses targeted to epidermal Langerhans cells to express fifteen HIV antigens in draining lymph nodes: 0.1 mg DNA targeted
to two, 0.4 mg and 0.8 mg DNA targeted to four lymph nodes. Particularly, in the medium dose cohort 0.1 mg DNA was
targeted per draining lymph node via ,8 million Langerhans cells located in 80 cm
2 epidermis area. The 28-days study with
48-week safety follow-up evaluated HIV-specific T cell responses against Gag p17, Gag p24 and Gag p15, Tat and Rev
antigens. DermaVir-associated side effects were mild, transient and not dose-dependent. Boosting of HIV-specific effector
CD4
+ and CD8
+ T cells expressing IFN-gamma and IL-2 was detected against several antigens in every subject of the
medium dose cohort. The striking result was the dose-dependent expansion of HIV-specific precursor/memory T cells with
high proliferation capacity. In low, medium and high dose cohorts this HIV-specific T cell population increased by 325-,
136,202 and 50,759 counts after 4 weeks, and by 3,899, 9,878 and 18,382 counts after one year, respectively, compared to
baseline.
Conclusions/Significance: Single immunization with the DermaVir candidate therapeutic vaccine was safe and
immunogenic in HIV-infected individuals. Based on the potent induction of Gag, Tat and Rev-specific memory T cells,
especially in the medium dose cohort, we speculate that DermaVir boost T cell responses specific to all the 15 HIV antigens
expressed from the single DNA. For durable immune reactivity repeated DermaVir immunization might be required since
the frequency of DermaVir-boosted HIV-specific memory T cells decreased during the 48-week follow up.
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Introduction
Currently, continuous administration of combination antiretro-
viral therapy (cART) is the standard care for the treatment of
HIV-infected individuals. cART effectively reduces viral load and
maintains undetectable HIV-RNA levels. These drugs significantly
increase survival of HIV-infected people, however, patients on
optimal cART still have 12 years shorter life expectancy than HIV
negative people [1]. cART does not decrease viral reservoirs,
including those located in gut-associated lymphoid tissues (GALT),
therefore if treatment is discontinued, the virus inevitably
rebounds [2,3]. Even intensification of cART with entry-,
protease- or integrase-inhibitors could neither decrease the viral
reservoirs nor increase HIV-specific immunity [4,5,6,7]. These
results proved that despite virologic success cART alone is unlikely
to cure HIV disease. It has been recently shown that the size of the
viral reservoir in the GALT inversely correlated with the
frequency of HIV-specific central-memory T cells [4,8]. These
data suggested that cART intensification with therapeutic
vaccination aimed at expanding HIV-specific T cell pool with
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e35416central-memory features bears the potential to accelerate clear-
ance of the viral reservoir.
DermaVir is a therapeutic vaccine, different from conventional
preventive vaccines aiming to protect healthy people against
infections. In contrast to preventive vaccines that must induce
antibody responses in uninfected subjects, therapeutic vaccines
must expand the HIV-specific memory T cell pool in patients who
have been already exposed to large amounts of HIV antigens and
developed both antibody and T cell responses not potent enough
to fully suppress viral replication. We hypothesized that it is
unlikely that simply injecting additional HIV antigens would have
any therapeutic effect. Therefore, we designed DermaVir as a
pathogen-like synthetic nanoparticle capable to express complex
Virus-like Particles (VLP
+) in dendritic cells. These VLP
+ antigens
preserve the structure and the epitope content of the wild-type
virus [9,10,11]. VLP
+- expressing dendritic cells can prime naı ¨ve
CD4
+ and CD8
+ T cells to expand the HIV-specific memory T
cell pool [12,13,14]. Proof of concept efficacy studies performed in
SIV251-infected macaques, some of them with AIDS, suggested
that DermaVir immunization alone or in combination with cART
could suppress viral load and improve survival of HIV infected
people [15]. The features of DermaVir immunization are depicted
in Figure 1.
Here we describe the first-in-human study conducted with the
DermaVir therapeutic vaccine candidate in Budapest, Hungary.
The aim of this Phase I dose escalation study was to evaluate safety
and tolerability of DermaVir immunization in HIV-infected
patients treated with fully suppressive cART and to compare the
immunogenicity of the different DermaVir doses. T cell responses
are usually measured after short-term peptide stimulation in an
IFN-gamma ELISPOT assay. These T cells are thought to
represent mainly effector-memory cells, which circulate shortly
after antigenic priming or recall [16]. It has been previously shown
that the quantity or frequency of HIV-specific T cells measured
after short antigenic stimulation are not associated with better
clinical outcome [17,18,19]. Measuring central-memory T cells,
on the other hand, requires antigenic re-stimulation, therefore we
utilized the PHPC (Precursors with High Proliferation Capacity)
assay to measure such immune reactivity. Others and we have
shown that the PHPC assay quantifies the memory T cells, a
distinct population from effector T cells, and these central-memory
T cells appear to play a key role in the protection from malaria,
HIV and HCV [20,21,22,23].
Methods
Study Design
The GIHU004 phase I trial was designed to evaluate the safety,
tolerability and immunogenicity of DermaVir immunotherapy in
individuals with chronic HIV-1 infection treated with fully
suppressive cART. The protocol for this trial and supporting
Figure 1. DermaVir immunization. (a) DermaVir administration area on the skin surface under 80 cm
2 large DermaPrep patches. The
immunization starts with a standardized skin preparation to interrupt the stratum corneum and activate Langerhans cells causing a mild and transient
erythema. (b) Cross-sectional view of the epidermis with approximately 8 million Langerhans cells estimated under one patch. (c) DermaVir
pathogen-like nanomedicine, a formulation to facilitate cellular entry, nuclear transport and expression of the plasmid DNA-encoded antigens. The
nanomedicine consists of the ‘‘core’’ that is a condensed plasmid DNA and a mannosylated polyethylenimine ‘‘envelope’’ [10,11]. (d) Needle-free,
topical, Langerhans cell-targeting vaccine administration with the DermaPrep device. The special semi-occlusive patch is kept on the skin for three
hours. (e) Activated epidermal Langerhans cells take up DermaVir, mature to antigen presenting dendritic cells and migrate to the draining lymph
nodes. (f) In the lymph node dendritic cells express the DNA-encoded antigens: 15 HIV proteins that assemble into a complex VLP
+ [9]. These cells
present several hundreds of epitopes to naı ¨ve T cells and prime HIV-specific precursor/memory T cells. (g) HIV-specific precursor/memory T cells with
high proliferative capacity circulate in the body to kill HIV-infected cells.
doi:10.1371/journal.pone.0035416.g001
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DermaVir nanomedicine was administered topically using the
DermaPrep device (see below) once, at study day 0. Subjects
remained in the clinic for observation for 3 hours after the
immunization. After 3 hours, the DermaPrep patches were
removed and the skin was evaluated. After four-week extensive
safety and immunogenicity evaluations, subjects were followed up
for an additional 48 weeks for safety.
Nine subjects were sequentially enrolled into each cohort.
Cohort 1: three subjects received a single low-dose DermaVir
immunization (0.1 mg pDNA/subject, 0.8 mL total volume of
DermaVir, administered topically with DermaPrep under two skin
patches). Further enrolment of subjects into the medium and high
dose cohorts began only after the safety data for the low and
medium doses cohorts were available and the criteria for enrolling
into the next cohort were met. The main criterion to enroll the
next dose cohort was the absence of a dose-limiting toxicity in any
of the DermaVir subjects in the prior cohort. Cohort 2: three
subjects received a medium-dose DermaVir immunization (0.4 mg
pDNA/subject, 3.2 mL total, administered topically with Derma-
Prep under four patches). Cohort 3: three subjects received a high-
dose DermaVir immunization (0.8 mg DNA/subject, 6.4 mL
total, administered topically with DermaPrep under eight patches).
Participants
The study population included nine HIV infected men and
women 18 to 50 years of age with a peak plasma HIV-1 RNA
.1,000 copies/mL before initiation of cART containing drugs of
at least two different classes. Eligible subjects had remained on a
stable cART regimen without changes or interruptions within the
24 weeks prior to study entry and had a plasma HIV-1 RNA level
,50 copies/mL measured at least twice within 12 weeks prior to
study entry. Subjects had a CD4
+ cell count .300 cells/mm
3 at
the time of entry, a nadir CD4
+ cell count .250 cells/mm
3 and
Karnofsky performance score $90. Exclusion criteria included
infection with hepatitis viruses (HBV, HCV), adhesive sensitivity,
use of immunomodulatory therapy or vaccine prior to study,
treatment with topical corticosteroids at vaccination sites, excessive
exposure to sun or tanning lights, and laser hair removal. Pregnant
women or patients with significant laboratory abnormalities were
also excluded, and all subjects were required to use an effective
contraceptive method during the study. Participants were recruit-
ed from the Szent La ´szlo ´ Hospital, Budapest, Hungary.
Ethics
The protocol and the informed consent was reviewed and
approved by the Local Ethics Committee and the Hungarian
National Institute of Pharmacy (OGYI) responsible for oversight of
the study. All study participants signed the informed consent.
Preparation of the Study Vaccine
The components of DermaVir were supplied by Genetic
Immunity (McLean, VA) in three separate vials. Vial 1 contained
1 mg/mL pLWXu1 plasmid DNA [9]; Vial 2 contained 13.6 mM
PEIm; Vial 3 contained 10% Dextrose/Glucose solution (USP)
[10].
The final manufacturing step of DermaVir was performed at
the clinic as described previously [10]. First the pDNA and the
PEIm was diluted with the sugar solution, then the two solutions
were mixed and the procedure were documented. The final
DermaVir product was kept at 4uC after formulation and
administered to the subject within 3 hours.
Topical Vaccination with DermaPrep
DermaVir was administered with DermaPrep medical device
(Genetic Immunity, McLean, VA). DermaPrep contains the
following material in a pouch: exfoliating sponge, stripping tapes
and skin patches (each for vaccination of an 80 cm
2 area). In
addition, the following materials are required for vaccine
administration: disposable razors, surgical markers, alcohol swabs,
syringes and needles to draw up the vaccine solutions (not for
injection).
DermaPrep skin sites included upper back and ventral upper
thigh. The skin site was shaved and disinfected using alcohol swab.
After the skin surface dried, it was rubbed with an exfoliating
sponge, then stripping tapes were applied to the skin site to remove
residual cell matter from the skin surface. The skin patch was
applied to the prepared skin site and the liquid vaccine was
injected with a needleless syringe under the pocket formed by the
patch on the surface of the skin. The pocket was then sealed and
the procedure was repeated for all remaining skin sites.
Preclinical safety and reactogenicity of topical DermaVir
vaccination conducted in swine and rabbits had previously
demonstrated that the major side effect of DermaVir vaccination
was transient mild erythema, due to the skin preparation
procedure required to the enhance skin penetration. Erythema,
a sign of inflammation, also provides the ‘‘danger signal’’ to
Langerhans cells to migrate to the draining lymph nodes [24,25].
Therefore, we do not consider transient, mild erythema during
DermaVir vaccination as a toxic side effect but rather as a signal
required for the efficacy of the transdermal administration process
with DermaPrep.
Study Endpoints
The primary outcome measured in GIHU004 was the
occurrence of at least one grade 3 or higher adverse event
including signs/symptoms, laboratory toxicities and clinical events
possibly, probably or definitely related to study treatment as
judged by the Principal Investigator or the site investigators during
the 28 days after DermaVir administration.
The following secondary endpoints were observed: CD4
+ and
CD8
+ T-cell counts/mL, HIV-1 RNA copies/mL ,50 copies/
mL, HIV-specific T cell responses; anti-DNA antibody responses,
tolerability as occurrence of premature study treatment discontin-
uation (i.e. less than three hours of patch application at all
designated sites) due to subject/physician requesting discontinu-
ation even though no protocol-defined toxicity endpoint had been
reached.
Assessment of Safety
Safety evaluations performed at each study visit (Day 0, Day 7,
Day 14, Day 28) included physical examination with local vaccine
site evaluation, hematology and blood chemistry, liver function
tests, urinalysis, CD4
+ and CD8
+ T cell counts and HIV-1 RNA.
Autoantibody testing for anti-nuclear antibodies (ANA) and anti-
double stranded DNA antibodies (anti-ds-DNA) was performed at
baseline and at Day 28. All these assays were included in the post-
treatment safety follow up evaluations performed at weeks 12, 24,
36 and 48.
Precursor/memory T Cell (PHPC) Assay
HIV-specific T cell precursors with high proliferative capacity
(PHPC) were quantified as described earlier [21]. Briefly, patients’
cryopreserved peripheral blood mononuclear cells (PBMC) were
plated and stimulated with HIV-1 peptides obtained from the
National Institutes of Health AIDS Research and Reference
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peptides with 11 amino-acid overlap corresponded to the complete
sequence of HIV-1 Consensus B Gag (p17, p24, p15), Tat, and
Rev. Positive control was PHA (Sigma-Aldrich), negative control
was the culture medium stimulation. Cells were cultured for 12
days in complete culture medium supplemented with IL-2 (R & D
Systems, Milan, It). On day 12, cells were tested in the same way
as the ELISPOT in response to the corresponding antigen used for
stimulation. PHPC assay was done in duplicates or triplicates and
results are presented as PHPC counts (net spots/million PBMC).
ELISPOT Assay
A human IFN-gamma ELISPOT kit (Diaclone, San Diego, CA)
was used according to the manufacturer’s protocol. HIV-1 peptide
pools (see PHPC assay) were diluted 1/200 in complete culture
medium and 0.1 mL was added to 0.1 million cells into each well.
PHA was the positive control and cells suspended only in complete
culture medium served as a negative control. Spots were counted
using automated ELISPOT reader system (A-EL-Vis). Results are
presented as ELISPOT counts (net spots/million PBMC).
ICC Assays
ICC (intra-cellular cytokine flow cytometry) assay quantifying
simultaneously CD4
+ and CD8
+ T cells producing IFN-gamma
and IL-2 was described previously [25,26]. Peptide pools described
for PHPC assay or mock were used as antigenic stimulation of
1 million PBMC for 6 h at 37uC. Brefeldin A (10 mg/mL; Sigma)
was added during the last 4 h of incubation. Red blood cells were
lysed and samples were permeabilized (PermFACS, Becton
Dickinson, UK) and stained with FITC-, PE-, PerCP- and
allophycocyanin (APC)-conjugated antibodies to IFN-gamma,
IL-2, CD4 and CD8 (BD Pharmingen, UK), respectively, and
fixed with 5% formaldehyde in PBS. Samples were analyzed on a
FACSCalibur flow cytometer using CellQuest Pro software by
gating first on the lymphocyte population identified by forward
and side scatter and on CD4
+- or CD8
+-bright populations and
then by analysis of IL-2 and IFN-gamma positive populations
within the CD4
+ and CD8
+ lymphocyte gates. The mean
frequencies of CD4
+ or CD8
+ T cells secreting the different
cytokines were calculated from triplicate assays.
Supersensitive HIV RNA Assay
NucliSens HIV-1 QT assay (bioMerieux, Inc. Durham NC) was
used according to the manufacturer’s protocol including the
improved elution of nucleic acids from silica particles and a color-
controlled precipitation of eluted nucleic acids followed by
isothermal transcription based nucleic acid amplification
(NASBA). The lower cutoff of the NucliSens is 5 copies/mL [27].
Statistical Analysis
Individuals in the cohorts were summarized using means and
compared using two-sided Wilcoxon Rank-Sum tests. All tests
were exploratory because of the small sample size.
Results
This Phase I study enrolled nine HIV-infected adult subjects.
All had durable suppression of HIV-RNA on cART over the
previous 6 months and CD4 count over 300 cells/mm
3 (Table 1).
Ten subjects were screened and one subject (08) failed to meet
entry criteria due to a history of bleeding and diabetes.
Nine subjects, in three sequential dose cohorts, received on
study Day 0 a single DermaVir immunization administered
topically with the DermaPrep device in three sequential cohorts.
Low dose: 0.1 mg pDNA, 0.8 mL DermaVir administered under
two DermaPrep patches. Medium dose: 0.4 mg pDNA, 3.2 mL
DermaVir administered under four DermaPrep patches. High
dose: 0.8 mg pDNA, 6.4 mL DermaVir administered under eight
DermaPrep patches. Subjects were on study for a total of 28 days
followed by a post-treatment safety follow-up for 48 weeks. cART
was not interrupted. All subjects completed the 28-day treatment
and 48 weeks safety follow up phase.
Adverse Events
All doses of DermaVir immunization were safe and well
tolerated. There was no death, no serious adverse event and no
discontinuation from the study. No subject reached the primary
endpoint of a grade 3 or higher adverse event including signs/
symptoms, laboratory toxicities and clinical events at least possibly
related to DermaVir treatment. We found that 2 of 9 subjects
developed a low grade fever and 4 of 9 subjects had minor skin
reactions (pruritus, scarring, skin hypersensitivity, erythema). All
adverse events at least possibly related to DermaVir are shown in
Table 2.
There were no treatment-emergent abnormal serum chemis-
tries, hematology values and vital signs judged to be clinically
significant. One of three subjects in every cohort experienced
grade 1 hematological abnormalities judged not related to study
treatment. Serum chemistry abnormalities were generally grade 1,
except two cART-related grade 2 abnormalities (Table 2). All
participants remained negative for both ANA and anti-ds-DNA
during the study. There were no differences in the frequencies of
adverse events among the cohorts.
Local skin reactogenicity assessed after the patches were
removed (3 hours after skin preparation and DermaVir admin-
istration) was limited to transient irritation and macular erythema
of mild severity at two of the eight vaccination sites in one patient.
Enlarged inguinal lymph nodes were observed in one subject in
the week following vaccination that resolved by the next visit
(Table 2).
HIV-RNA, CD4 and CD8 Cell Counts
In all the subjects plasma HIV RNA levels were ,50 copies/
mL prior to and during the study, suggesting that DermaVir
immunization was not associated with measurable viral load
activation or blips. In an attempt to detect even minimal viral load
decreases HIV-RNA levels were evaluated with a supersensitive
PCR assay. Eight of nine patients had ,5 copies/mL prior
(Table 1) and all the patients had ,5 copies/mL 28 days following
immunization (data not shown).
CD4 counts generally increased from baseline to Week 4 and
Week 48 in the low and median dose cohorts and decreased in the
high dose cohort (Table 3). There were no changes in any subject’s
antiretroviral drug regimen during the 48 weeks of observation.
HIV-specific T Cells Detected After Short-term Antigenic
Stimulation
HIV Gag, Tat and Rev specific ELISPOT responses detected
during the study are shown in Table 4. We considered as
responders the subjects having $10 fold higher ELISPOT
responses compared to baseline (bold labeled). Generally, the
pre-immunization (baseline) values to HIV antigens were low as
expected after long-term fully suppressive cART [28]. DermaVir
boosted ELISPOT responses in 2 out of 3 subjects in the low dose
cohort and all 3 subjects in the medium dose cohort. All the
responder had Gag-specific T cells. There were no responses to
any antigens in the high dose cohort.
Phase I Trial with DermaVir Therapeutic HIV Vaccine
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ICC assay to detect the responding CD4
+ and CD8
+ T cell
population secreting IFN-gamma and IL-2 (Table 5). Generally,
the percentages of cytokine secreting T cells within the T cell
populations were low. However, we found that ELISPOT
responders of the medium dose cohort were also ICC responders.
These subjects had both CD4
+ and CD8
+ T cell responses to Gag,
Tat and Rev stimulation. Some of the CD8
+ T cells produced both
IFN-gamma and IL-2, the CD4
+ T cells mostly IL-2 cytokines. In
the low dose and high dose cohorts we could only sporadically
detect T cell responses. The lack of HIV-specific ICC responses in
the low dose cohort despite positive ELISPOT reflects the lower
sensitivity of the ICC assay.
HIV-specific Precursor/Memory T Cells
HIV-specific precursors with high proliferative capacity (PHPC)
were evaluated before and after single DermaVir immunization.
Figure 2 demonstrates the kinetics of the PHPC responses to Gag
p17, Gag p24, Gag p15, Rev and Tat of every subjects measured
before immunization (week 0) and 1, 2, 4, and 48 weeks after
immunization. All subjects had consistent low or undetectable
PHPC counts prior to DermaVir immunization, averages being
between 15 and 36 counts (net spots/million PBMC) per peptide
pools. We found that DermaVir immunization induced PHPC
responses in every patient within 28 days. In the low dose cohort
there was a modest (+325) immune boosting (Table 6). In striking
contrast, DermaVir immunization boosted the PHPC responses
by 136,202- and 50,759 counts compared to baseline in the
medium and in the high dose cohorts, respectively. We found
statistically significant PHPC increases between baseline and day
28 for the nine subjects for total Gag, Gag p24, Gag p15, Rev, Tat
(p#.01) and Gag p17 ((p#.05). This statistically significant
increase of immune responses after vaccination of HIV-infected
people demonstrates the immunogenicity of the study vaccine.
The high dose cohort responses did not exceed the medium dose
ones, albeit the differences between the PHPC responses of the two
cohorts were not statistically significant. The PHPC counts were
higher in the medium and high dose cohorts compared to the low
dose at day 28 (p#.1). The strongest responder was subject 06,
who had undetectable PHPC responses to every assayed antigens
Table 1. Baseline data of study participants.
*Cohort (Code) Gender Age cART Nadir CD4 Baseline CD4 Baseline CD8 HIV RNA
1 (01) F 50 Combivir Efavirenz 530 908 484 ,5
1 (02) M 43 Didanosine Tenofovir Kaletra 261 507 1335 ,5
1 (03) M 42 Combivir Efavirenz 350 860 789 ,5
2 (04) F 32 Combivir Efavirenz 317 626 1050 ,5
2 (05) M 39 Combivir Kaletra 296 721 823 37
2 (06) M 39 Combivir Efavirenz 392 822 940 ,5
3 (07) M 46 Zidovudine Lamivudine Kaletra 327 1050 2047 ,5
3 (09) M 29 Combivir Efavirenz 294 524 432 ,5
3 (10) M 32 Combivir Indinavir Ritonavir 257 528 563 ,5
*Cohort 1: Low dose DermaVir (0.1 mg DNA); Cohort 2: Medium dose DermaVir (0.4 mg DNA); Cohort 3: high dose DermaVir (0.8 mg DNA). All participants were
Caucasian and was negative for ANA and anti-ds-DNA; F: Female; M: Male. CD4 in counts/mm
3.
doi:10.1371/journal.pone.0035416.t001
Table 2. All Adverse Events judged attributable to DermaVir immunization.
DermaVir Dose Cohorts Code Adverse Events (Grade)
DermaVir-related DermaVir-unrelated
Low (1) 01 Lumbago (1)
02 Fever (1)
Pruritus (1)
Myalgia (1)
03 Chills and 37.6uC fever (1)
Palpable lymph nodes of left foss.
Femoralis (1) Right shoulder scar caused by the tape (1)
Triglycerides (2)
Medium (2) 04 None
05 Fatigue (1)
Skin hypersensitivity (1)
Hyperbilirubinemia (2)
06 None
High (3) 07 Macular Erythema (1) Hyperbilirubinemia (2)
09 None
10 Nausea (1)
Eosinophilia (1)
Triglycerides (2)
doi:10.1371/journal.pone.0035416.t002
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responses: ,30,000 counts to both Tat and Rev, ,50,000 counts
to both Gag p17 and Gag p15 and ,150,000 counts to Gag p24.
Although it generally took 4 weeks following a single DermaVir
vaccination to detect new precursor/memory T cells, the
responses were durable up to one year. All samples of each
patient were assayed from frozen PBMC specimen in duplicates or
triplicates at the same time by the same operator and with the
same reagents.
Long-term Follow Up
All subjects had a 48 weeks safety follow up. There were no
significant adverse events or withdrawals, and no adverse events
judged to be related to or possibly related to DermaVir
immunization. No subject modified cART during the course of
48 weeks safety period.
The long-term immunogenicity of a single DermaVir immuni-
zation was observed in every patient (Figure 2). The expansion of
PHPC responses in cohorts 1, 2 and 3 compared to the baseline
increased by 3,899, 9,878 and 18,382 counts, respectively. Within
the total assayed PHPC counts statistical significant increases were
detected for total Gag, Gag p17, Gag p24, Gag p15 and Tat, but
not for Rev responses (p#.01). In the low dose cohort PHPC
responses increased in 6 months compared to the previous time-
points. In the medium and high dose cohorts PHPC responses
decreased .10 fold in 11 months in five out of six subjects.
Discussion
The GIHU004 study demonstrated the safety and tolerability of
all three DermaVir doses in HIV-infected patients treated with
fully suppressive cART. DermaVir-related side effects were mild
and transient, without dose limiting toxicities. Consistent with
findings from the preclinical studies, skin reactogenicity was due to
the skin preparation procedure, and the mild erythema induced
during the skin preparation to activate the epidermal Langerhans
cells was typically no longer visible when the patches were
removed 3 hours later. DermaVir immunization did not increase
viral load. Decrease of HIV-RNA could be only detected in one
subject because all other subjects had HIV-RNA level ,5 copies/
mL prior to immunization. CD4 counts increased in the low and
medium dose cohorts, no dose-relationship was observed.
Long-term successful cART results in the suppression of antigen
concentration and the decrease of HIV-specific T cells [27].
Accordingly, we found in our study population very low or
undetectable HIV-specific T cell responses measured by ELI-
SPOT, ICC and PHPC assays prior to DermaVir immunization.
These results confirmed that optimal cART suppresses the body’s
own defense mechanism that would be necessary to eliminate the
infected cells remained in the reservoirs [4,8].
Table 3. CD4
+ and CD8
+ T cell counts.
Cohorts
(Code) CD4 counts/mm
3 CD8 counts/mm
3
Study weeks
044 8 044 8
1 (01) 908 1,140 998 484 510 528
1 (02) 507 361 515 1,335 883 1,287
1 (03) 860 1,179 1,187 789 1,149 1,413
2 (04) 626 909 551 1,050 1,636 866
2 (05) 721 774 820 823 831 890
2 (06) 822 852 1,043 940 1,113 911
3 (07) 1,059 834 901 2,047 1,222 1,650
3 (09) 524 528 443 432 455 488
3 (10) 528 501 633 563 509 680
doi:10.1371/journal.pone.0035416.t003
Table 4. HIV-specific ELISPOT responses.
Cohort 1 Cohort 2 Cohort 3
01 02 03 04 05 06 07 09 10
Gag p17 (0) 0 25 10 10 20 5 30 35 50
(weeks) (4) 80 0 7 330 80 65 05 00
(48) 85* 255* 0* 325 40 370 35 15 15
Gag p24 (0) 0 30 14 5 05 45 110 95
(weeks) (4) 290 52 0 5 390 920 65 270 0
(48) 1475* 0* 43* 10 895 1370 08 04 0
Gag p15 (0) 10 255 24 5 5 10 15 20 155
(weeks) (4) 30 10 30 45 25 210 10 65 10
(48) 305* 340* 100* 130 20 830 05 57 0
Tat (0) 0 30 7 00 020 0 200
(weeks) (4) 10 01 7 53 5 4 0 04 01 5
(48) 15* 55* 27* 35 55 320 55 0 45
Rev (0) 1 35 10 00 55 0 9 0
(weeks) (4) 10 0 0 55 09 0 5 0
(48) 0* 15* 0* 30 5 40 10 0 5
ELISPOT SFU/10
6 PBMC are the average of a duplicate or triplicate assay; Mocks were subtracted.
*Cohort 1 samples were collected at week 24. Bold: ELISPOT responders: $10 fold above the response at baseline.
doi:10.1371/journal.pone.0035416.t004
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dose-dependent expansion of HIV-specific precursor/memory T
cells with high proliferation capacity. In the low dose cohort we
have consistently found low frequency of PHPC responses
suggesting that suboptimal amount of DermaVir DNA expressed
in the lymph nodes. In the medium and high dose cohorts we
found very high frequency of PHPC responses: for all five HIV
antigen stimulation the precursor/memory T cells significantly
Table 5. HIV-specific ICC responses.
Cohorts
(Code) Gag p17 Gag p24 Gag p15 Tat Rev
CD8 CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 CD4
1 ( 0 1 ) ––––––––––
1 ( 0 2 ) ––––––––––
1 ( 0 3 ) I F N –––––––––
2 (04) IFN IL2 – – – IFN IL2 – IFN IL2 IL2 IFN IL2 IFN
2 (05) IL2 IL2 IL2 IL2 IL2 IL2 IL2 IL2 IL2 IL2
2 (06) IL2 IL2 IL2 IFN – IL2 IFN IL2 IL2 IL2 IL2 IFN IL2
3 ( 0 7 ) I F N ––I F N ––––––
3 ( 0 9 ) I F N –I F N –––––––
3 ( 1 0 ) I L 2 –––––––I F N I L 2 –
Responders: at least 2 separate visits .baseline and/or response is $2% (net cytokine producing CD4 or CD8 T cells).
doi:10.1371/journal.pone.0035416.t005
Figure 2. Kinetics of the HIV-specific PHPC responses. Long-lived HIV-specific precursor/memory T cells with high proliferative capacity prior
and after a single DermaVir immunization in each HIV-infected individual on fully suppressive cART. 1
st raw: Low dose; 2
nd raw: Medium Dose; 3
rd raw:
high dose DermaVir immunizations. Frequency of PHPC responses against Tat, Rev and the three Gag antigens are shown prior (Day 0) and after
DermaVir immunization (day 7, day 14, day 28, and week 48). Every sample was assayed in duplicate or triplicate, and data are shown as PHPC counts/
10
6 PBMC.
doi:10.1371/journal.pone.0035416.g002
Phase I Trial with DermaVir Therapeutic HIV Vaccine
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e35416expanded, sometimes over 2,000 fold compared to baseline. All
the immunogenicity data (PHPC, ICC and ELISPOT) demon-
strated the absence of additional benefit after increasing the
DermaVir dose from the medium to high dose. DermaVir’s
immune reactivity was slow, peaking four weeks after immuniza-
tion. Such delayed kinetics is consistent with the naı ¨ve T cell
priming and with the conversion to antigen-specific central
memory T cells [29].
DermaVir dose escalation involved not only the administration
of more vaccine. We investigated three options: (i) increase the
DermaVir dose on the same skin surface area (low to medium
dose), (ii) use different location of the skin to target the vaccine to
different lymph nodes (low to medium dose), and (iii) increase the
skin surface area to target more vaccine containing Langerhans
cells to the same draining lymph nodes (medium to high dose). In
the low dose we targeted 0.1 mg DNA to two lymph nodes. In
medium and high doses we have targeted 0.4 mg and 0.8 mg
DNA in four lymph nodes, respectively. We found that
simultaneous T cell priming in different lymph nodes was required
to induce the highest frequency of HIV-specific T cells. Based on
the immunological outcome of the study (Tables 4, 5 and 6), we
concluded that the optimal boosting of T cell responses by
DermaVir was achieved in the medium dose cohort. In the
medium dose cohort 0.1 mg DNA was targeted per draining
lymph node via ,8 million Langerhans cells located in 80 cm
2
epidermis area. Doubling the amount of antigens per lymph nodes
(high dose) did not increase the T cell responses. Decreasing the
amount of antigens per lymph nodes (low dose) resulted in lower
quantity of immune responses.
DermaVir induced precursor/memory T cell responses are
particularly interesting since they have functional characteristics of
central-memory T cells. In macaques DermaVir has induced
potent CD4
+ and CD8
+ T cells with similar central-memory
phenotype [14]. PHPC immune reactivity is associated with low
plasma viremia and preserved CD4
+ T cell counts and is
quantitatively and qualitatively different from the T cells measured
by the ELISPOT assay [21]. In this clinical study we could not
phenotype DermaVir-induced T cells, however the following data
suggested that they have HIV-specific central-memory T cell
properties: (i) they are new HIV-specific T cells (compared to pre-
immunization baseline); (ii) they are HIV-specific (mock control
was subtracted); (iii) they are capable to extensive proliferation on
Table 6. Increase of HIV-specific memory/precursor T cells from baseline after a single DermaVir immunization.
Dose Antigen Mean PHPC counts (net spots/million PBMC) (SD)**
Low (1) Baseline* Increase at Day 28 Increase at Week 24
Total Gag 85 (55) +226 (238) +3,496 (1,095)
p17 45 (23) +66 (108) +181 (218)
p24 28 (29) +69 (48) +1,397 (227)
p15 12 (11) +92 (90) +1,918 (1,391)
Rev 13 (11) +57 (50) +10 (33)
Tat 6 (10) +41 (44) +393 (340)
Gag+Rev+Tat*** 104 (67) +324 (266) +3,899 (869)
Medium (2) Baseline* Increase at Day 28 Increase at Week 48
Total Gag 9 (15) +109,715 (133,082) +9,627 (10,429)
p17 0 (0) +19,824 (34,274) +604 (541)
p24 3 (5) +67,260 (75,749) +7,990 (11,239)
p15 6 (10) +22,631 (25,609) +1,032 (1,394)
Rev 0 (0) +13,499 (14,829) 0 (0)
Tat 0 (0) +12,988 (15,013) +251 (435)
Gag+Rev+Tat*** 9 (15) +136,202 (162,287) +9,878 (10,257)
High (3) Baseline* Increase at Day 28 Increase at Week 48
Total Gag 65 (106) +43,468 (42,301) +15,632 (18,684)
p17 12 (16) +9,171 (15,847) +2,812 (2,300)
p24 34 (58) +22,909 (21,746) +10,114 (14,296)
p15 19 (32) +11,388 (5,361) +2,706 (2,535)
Rev 14 (24) +5,293 (3,372) +694 (813)
Tat 27 (47) +1,998 (1,574) +2,056 (2,198)
Gag+Rev+Tat*** 106 (91) +50,759 (44,792) +18,382 (21,477)
*Calculated from data of the 2 separate PBMC specimen obtained from every subjects at screening and at day 0, just before DermaVir immunization.
**PHPC counts were calculated as follows: (Proliferation index) x (mean number of spots/million PBMC in wells from each pool of peptides - mean number of spots/
million PBMC in wells with control medium). PHPC counts in response to Gag p17 pool, Gag p24 pool and Gag p15 pool were summed to calculate total Gag responses
(denoted as Gag).
***Gag+Tat+Rev responses were calculated by adding Gag, Rev and Tat responses together; it represents ,25% of the total immunologic potential of DermaVir [9].
doi:10.1371/journal.pone.0035416.t006
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secrete IL-2 (shown by the ICC assay); (v) they appear in the
peripheral blood 4 weeks after DermaVir immunization and, (vi)
they persist .48 weeks after DermaVir immunization in HIV-
infected people, albeit in lower quantity. These clinical findings
support our hypothesis that immune responses induced by
DermaVir that expresses VLP
+ in the dendritic cells of the lymph
nodes are different than vaccines targeting the somatic cells, e.g.
those employing viral vectors or injected/electroporated DNA
[30].
DermaVir induced precursor/memory T cells had broad
specificity. We measured DermaVir’s immune reactivity with five
overlapping peptide pools representing regulatory HIV proteins
that are expressed very early during the viral life cycle and
structural HIV proteins that are expressed late. However, the total
T cell responses boosted by DermaVir were not limited to these
antigens. DermaVir’s active pharmaceutical ingredient is a novel
plasmid DNA (pLWXu1) that expresses all 15 HIV antigens and
consequently has the highest epitope coverage within HIV vaccine
candidates [9]. Gag p24 expression, also used to assess the potency
of DermaVir, quantifies both the expression of all the regulatory
and structural HIV proteins from the plasmid DNA and the
release of a VLP
+ [9]. By calculating the T cell responses induced
by DermaVir we found that the five peptide-pools only measured
approximately 25% of the total T cell responses potentially
induced by DermaVir [9]. Since beside Gag p24 we also measured
very potent induction of Gag p17, Gag p15, Tat and Rev-specific
precursor/memory T cells, we speculate that DermaVir induced
additional T cell responses specific to Protease, Reverse transcrip-
tase, RNase, Integrase (truncated), Env gp120, Env gp41, Nef
(truncated), Vif, Vpu and Vpr in the medium and in the high dose
cohorts.
Initiation of therapy early in the course of HIV infection has
been recently suggested to preserve immune functions and
improve long-term outcomes [31,32]. However, one limitation of
early cART is the decrease of HIV-specific immunity. We propose
cART intensification with DermaVir to boost the long-lived HIV-
specific precursor/memory T cell pool. Our data suggest that
maintenance of such immune reactivity might require repeated
DermaVir immunization. This concept is supported by recent
findings showing that the half-life of central-memory T cells is
between 28 and 100 days in HIV infected subjects and these cells
have shorter half-life and reduced frequency, particularly in those
with high viral load [33]. The antiviral efficacy of DermaVir must
be determined in larger trials to confirm the viral load and survival
benefits found in infected macaques [15]. To address HIV
variability, the plasmid DNA in the DermaVir could be adapted to
provide personalized treatment possibilities by matching T cell
responses with epitopes presented by the patients’ cells.
All preclinical and clinical data obtained to date imply that
DermaVir therapeutic vaccine candidate might provide a novel,
effective and accessible treatment option for individuals infected
with HIV-1.
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